Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, Ireland
Horizon purchased its existing facility in
“As we grow as a global biotechnology company, it is important to continue to invest in our development and manufacturing capabilities to supplement our current network of contract manufacturing organizations to maintain flexibility over our production and supply,” said
About Horizon
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential expansion of Horizon’s manufacturing facility, Horizon’s expected use of the facility, timelines for regulatory approvals and release of medicine from Horizon’s existing facility, and expectations regarding job creation as a result of the expanded facility. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the planning application and regulatory approval processes, changes in circumstances that could cause Horizon to modify its plans or actual uses of the facility, potential delays in the planning application, construction, validation or regulatory approval processes, and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220828005031/en/
Senior Vice President, Chief Investor Relations Officer
Investor-relations@horizontherapeutics.com
Executive Vice President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
Ireland Media:
Gordon MRM
ray@gordonmrm.ie
Source: